September 9, 2026
Bonus Content: Abbott’s Libre Duo Just Got FDA Clearance. The Stock Hasn’t Noticed.
Copper is at record highs. Gold just blasted to $5K.
And while most juniors are forced to repeatedly raise money to keep the drills turning… this sub – $1 copper-gold explorer has one of the world’s largest gold producers funding the work.
That’s a huge advantage.
Meanwhile, shares still trade below $1.
And major-company-funded drilling is only the beginning.
Across two premier Australian mineral belts, drills are turning with plenty of firepower for what comes next:
✔ Major-company-funded exploration Down Under
✔ An aggressive new multi-project drill campaign
✔ Multiple paths to copper-gold discovery
✔ A strong treasury and tight share structure
✔ BONUS: Our exclusive interview with the CEO
That’s a lot of upside packed into a sub – $1 stock.
Click here to access our FREE online report… and discover why this under-the-radar copper-gold explorer has all the ingredients for a major breakout as the drills turn Down Under.
Abbott’s Libre Duo Just Got FDA Clearance. The Stock Hasn’t Noticed.
On August 25, 2026, Abbott Laboratories received FDA De Novo authorization for the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, the first wearable cleared to continuously monitor glucose and ketone levels. That is a genuine regulatory first. The market’s reaction, so far, has been a collective shrug.
Year to date, ABT shares have declined in the low-to-mid teens, while DexCom shares are up double digits.
What Libre Duo Does Differently
Branded as Libre Duo 10 Day, the sensor provides real-time visibility into glucose levels as a standard CGM does, but also into ketone levels that can rise ahead of a diabetic ketoacidosis emergency, continuously monitoring both analytes to reduce reliance on tests that capture only a single moment in time. No existing CGM on the market does both simultaneously.
De Novo is the pathway the FDA uses for novel low-to-moderate-risk devices that have no existing predicate. That classification matters: it creates a head start competitors cannot replicate simply by filing against an existing cleared device. Dexcom has no dual-analyte product on the market at a comparable stage.
The Revenue Base Behind the Catalyst
Q2 CGM sales reached $2.188 billion, growing 9.5% on a comparable basis. The underlying Libre franchise is not broken. Q1 growth came in the high single digits but was weighed down by an international tender delay and a tough prior-year comparison tied to shelf restocking. Both headwinds were temporary and management flagged as much on the Q1 call.
Abbott has said it leads the global CGM market, and CEO Robert Ford has estimated that 70 to 80 million people globally should be using CGMs compared with the current market of roughly 10 to 12 million users. Libre Duo, targeting a DKA-prone subset of that addressable pool, is a wedge into a patient group that previously required separate blood or urine ketone testing.
Why the Stock Lags
The disconnect between product momentum and share price traces to three things. Abbott faces respiratory testing volatility in Diagnostics, dilution risk following the Exact Sciences acquisition, and ongoing uncertainty in China. The Exact Sciences deal introduced a $0.20 dilution to 2026 adjusted EPS guidance of $5.38 to $5.58. Those are real costs that sit on top of a stock that was already de-rated.
Abbott is trading below its own longer-term valuation averages on several common metrics. That gap reflects the market pricing in the near-term drag rather than the longer product cycle.
What Traders Watch Next
Over the next 12 months, Ford has pointed to milestones including a U.S. launch cadence that includes Libre Duo, Amulet 360, and TactiFlex Duo PFA. Libre Duo’s commercial timing will matter, but the bigger swing factor is how quickly payers treat dual-analyte monitoring as a reimbursable step-up versus a niche add-on.
The reimbursement path is the real unlock. Type 2 non-insulin reimbursement remains a major potential upside lever, and Abbott has highlighted a large population that is not consistently covered today. If Medicare coverage expands meaningfully to that group, the revenue math changes materially. Until that decision lands, ABT’s beaten valuation and a first-mover dual-sensor clearance represent an asymmetric situation worth tracking into year-end.
